Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.

Zhang H, Zhang A, Kohan DE, Nelson RD, Gonzalez FJ, Yang T.

Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9406-11.

2.

PPARγ agonist-induced fluid retention depends on αENaC expression in connecting tubules.

Fu Y, Gerasimova M, Batz F, Kuczkowski A, Alam Y, Sanders PW, Ronzaud C, Hummler E, Vallon V.

Nephron. 2015;129(1):68-74. doi: 10.1159/000370254.

3.

Peroxisome proliferator-activated receptor-γ agonists repress epithelial sodium channel expression in the kidney.

Borsting E, Cheng VP, Glass CK, Vallon V, Cunard R.

Am J Physiol Renal Physiol. 2012 Mar 1;302(5):F540-51. doi: 10.1152/ajprenal.00306.2011.

4.

Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.

Guan Y, Hao C, Cha DR, Rao R, Lu W, Kohan DE, Magnuson MA, Redha R, Zhang Y, Breyer MD.

Nat Med. 2005 Aug;11(8):861-6.

PMID:
16007095
5.

Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters.

Zhou L, Liu G, Jia Z, Yang KT, Sun Y, Kakizoe Y, Liu M, Zhou S, Chen R, Yang B, Yang T.

Am J Physiol Renal Physiol. 2013 Nov 15;305(10):F1491-7. doi: 10.1152/ajprenal.00004.2013.

6.

Rosiglitazone activates renal sodium- and water-reabsorptive pathways and lowers blood pressure in normal rats.

Song J, Knepper MA, Hu X, Verbalis JG, Ecelbarger CA.

J Pharmacol Exp Ther. 2004 Feb;308(2):426-33.

7.
8.

Thiazolidinedione-induced fluid retention is independent of collecting duct alphaENaC activity.

Vallon V, Hummler E, Rieg T, Pochynyuk O, Bugaj V, Schroth J, Dechenes G, Rossier B, Cunard R, Stockand J.

J Am Soc Nephrol. 2009 Apr;20(4):721-9. doi: 10.1681/ASN.2008040415.

9.

Peroxisome proliferator-activated receptor gamma antagonists decrease Na+ transport via the epithelial Na+ channel.

Pavlov TS, Levchenko V, Karpushev AV, Vandewalle A, Staruschenko A.

Mol Pharmacol. 2009 Dec;76(6):1333-40. doi: 10.1124/mol.109.056911.

10.

A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.

Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, Meinke PT, Thompson JR, Doebber TW, Berger JP, McCann ME.

Eur J Pharmacol. 2008 Apr 14;584(1):192-201. doi: 10.1016/j.ejphar.2007.12.036.

PMID:
18346728
11.

Brain PPAR-γ promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones.

Lu M, Sarruf DA, Talukdar S, Sharma S, Li P, Bandyopadhyay G, Nalbandian S, Fan W, Gayen JR, Mahata SK, Webster NJ, Schwartz MW, Olefsky JM.

Nat Med. 2011 May;17(5):618-22. doi: 10.1038/nm.2332.

12.

T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.

Li Y, Wang Z, Furukawa N, Escaron P, Weiszmann J, Lee G, Lindstrom M, Liu J, Liu X, Xu H, Plotnikova O, Prasad V, Walker N, Learned RM, Chen JL.

J Biol Chem. 2008 Apr 4;283(14):9168-76. doi: 10.1074/jbc.M800104200.

13.

Review article: importance of the kidney proximal tubular cells in thiazolidinedione-mediated sodium and water uptake.

Panchapakesan U, Pollock C, Saad S.

Nephrology (Carlton). 2009 Apr;14(3):298-301. Review.

PMID:
19444964
14.

PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.

Kim MK, Chae YN, Kim HS, Choi SH, Son MH, Kim SH, Kim JK, Moon HS, Park SK, Shin YA, Kim JG, Lee CH, Lim JI, Shin CY.

Arch Pharm Res. 2009 May;32(5):721-7. doi: 10.1007/s12272-009-1511-8.

PMID:
19471887
15.

An insulin-sensitizing thiazolidinedione, which minimally activates PPARγ, does not cause bone loss.

Fukunaga T, Zou W, Rohatgi N, Colca JR, Teitelbaum SL.

J Bone Miner Res. 2015 Mar;30(3):481-8. doi: 10.1002/jbmr.2364.

17.

Role of the EGF receptor in PPARγ-mediated sodium and water transport in human proximal tubule cells.

Saad S, Zhang J, Yong R, Yaghobian D, Wong MG, Kelly DJ, Chen XM, Pollock CA.

Diabetologia. 2013 May;56(5):1174-82. doi: 10.1007/s00125-013-2835-y.

PMID:
23370527
18.

Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin.

Galli A, Ceni E, Mello T, Polvani S, Tarocchi M, Buccoliero F, Lisi F, Cioni L, Ottanelli B, Foresta V, Mastrobuoni G, Moneti G, Pieraccini G, Surrenti C, Milani S.

Hepatology. 2010 Aug;52(2):493-505. doi: 10.1002/hep.23669.

PMID:
20683949
19.

Thiazolidinediones alter growth and epithelial cell integrity, independent of PPAR-γ and MAPK activation, in mouse M1 cortical collecting duct cells.

Nasrallah R, Clark J, Corinaldi J, Paris G, Miura P, Jasmin BJ, Hébert RL.

Am J Physiol Renal Physiol. 2010 May;298(5):F1105-12. doi: 10.1152/ajprenal.00735.2009.

Items per page

Supplemental Content

Support Center